Bruker acquires majority share in Biognosys

The Bruker Corporation, a specialist in the analysis of biologics with headquarters in Billerica in the U.S. state of Massachusetts, and Biognosys AG based in the Bio-Technopark Schlieren-Zurich have announced a strategic partnership. According to a press release, Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed.

Several of Biognosys’ existing investors sold their shares to Bruker in a secondary transaction and Bruker will make new primary investments in Biognosys. The Co-Founder and CEO Oliver Rinner and his leadership team will continue to manage Biognosys.

Thanks to this investment from Bruker, the spin-off from the Swiss Federal Institute of Technology in Zurich now plans to open a laboratory in the USA. The new strategic partnership will broaden customer access to Biognosys’ leading CRO services and Spectronaut software tools for unbiased proteomics and epiproteomics.

Rinner highlights the close collaboration of the two partners to support Bruker’s high-throughput, deeper proteomics methods within the Spectronaut software from Biognosys. “Biognosys remains committed to maintaining Spectronaut as a high-performance vendor-agnostic proteomics software,” he explains. The laboratory in Massachusetts will use a special platform from Bruker, “so that our customers can benefit from multiple MS technologies”.